Yan Nikhamin - New York City Metropolitan Area
Applying a clinical lens to animal models of CAR-T cell therapies
Frontiers Cancer Therapy With TCR-Engineered T Cells: Current
Yan Nikhamin - New York City Metropolitan Area
Natural killer cells activity against multiple myeloma cells is
Issue: Molecular Therapy
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for
Yan Nikhamin - New York City Metropolitan Area
Frontiers CAR T-Cell Therapy Predictive Response Markers in
Coengineering specificity, safety, and function into T cells for
Host-cell Interactions of Engineered T cell Micropharmacies
Yan Nikhamin - New York City Metropolitan Area
Frontiers Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling